Novel approaches
to vascular therapy

Angios is a biotechnology company, specializing in vascular research to improve
patients' lives all over the world. We are based in Innsbruck, Austria

The need

Blood vessels are the lifelines of our body. Diseases affecting their functionality remain one of the big unresolved global health problems. Especially diabetic patients suffer from a multitude of vascular complications that can cause blindness, non-healing wounds and kidney failure.

The solution

Angios strives to develop new treatments for these challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.
More information

Press release

The Founders
The Founders
The Founders
The Founders
The Founders
The Founders
The Founders

Prof. Josef
Penninger, MD

Chairman
Josef is currently the Director of the Life Sciences Institute at the University of British Columbia and was the founding Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences. He co-authored over 700
Show CV

Dr.
Gregor Wick

CEO
Gregor is an entrepreneur and consultant in the life sciences and biotech arena for 30 years. He worked with global management
Show CV

David
Hoffmann, PhD

CSO
David holds a PhD in molecular biology from the University of Vienna and has experience in tumor angiogenesis and tumor glycosylation.
Show CV